Business Context and Reporting Period
This Form 8-K is filed by 180 Life Sciences Corp. (not Forum Markets Inc.) on October 17, 2024, with a report date of October 17, 2024. The filing details a warrant inducement agreement executed on October 16, 2024, and subsequent warrant exercises and issuances on October 16 and 17, 2024. The company is incorporated in Delaware and trades on the NASDAQ under the symbols ATNF (Common Stock) and ATNFW (Warrants).
Key Financial Metrics and Transaction Details
- Cash Proceeds: The company received $3,306,240 from the full cash exercise of existing warrants by a specific holder.
- Shares Issued: 950,069 shares of Common Stock were issued upon the exercise of existing warrants.
- New Warrants Issued: The company issued new unregistered warrants to purchase up to 1,900,138 shares of Common Stock.
- New Warrant Terms: Exercise price of $1.50 per share; immediately exercisable; five-year term.
- Existing Warrant Exercise Price: $3.48 per share.
- Outstanding Shares: Following the issuance, the total shares of Common Stock issued and outstanding will be 1,976,999.
Material Changes and Corrections
This filing serves as a correction to a Prior Form 8-K filed on October 16, 2024. The following figures were corrected:
- Existing Warrant Shares: Corrected from 954,118 to 950,069 shares.
- Proceeds Raised: Corrected from approximately $3,320,331 to $3,306,240 (before deducting financial advisory fees and other expenses).
Guidance, Outlook, and Risks
The filing does not provide forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard securities law disclosures. The issuance of New Warrants was exempt from registration under Section 4(a)(2) and/or Rule 506 of the Securities Act of 1933, as the transaction did not involve a public offering and the recipient was an accredited investor. The securities are subject to transfer restrictions.
Investor Verification Checklist
- Verify the corrected cash proceeds of $3,306,240 and the exact share count of 950,069 issued from the warrant exercise.
- Confirm the total outstanding share count of 1,976,999 following the transaction.
- Review the terms of the New Warrants (1,900,138 shares at $1.50 exercise price) and their potential dilutive impact.
- Check the Prior Form 8-K (filed October 16, 2024) for the full context of the Inducement Agreement and beneficial ownership limitations.
- Note that the filing entity is 180 Life Sciences Corp., not Forum Markets Inc.